Jason S Knight

List of Publications by Citations

Source: https://exaly.com/author-pdf/7657979/jason-s-knight-publications-by-citations.pdf

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

102
papers7,739
citations41
h-index87
g-index109
ext. papers10,008
ext. citations7.7
avg, IF6.24
L-index

#	Paper	IF	Citations
102	Targeting potential drivers of COVID-19: Neutrophil extracellular traps. <i>Journal of Experimental Medicine</i> , 2020 , 217,	16.6	795
101	NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. <i>Science Translational Medicine</i> , 2013 , 5, 178ra40	17.5	726
100	Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease. <i>Nature Medicine</i> , 2016 , 22, 146-53	50.5	721
99	Neutrophil extracellular traps in COVID-19. <i>JCI Insight</i> , 2020 , 5,	9.9	575
98	Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease. <i>Journal of Immunology</i> , 2012 , 188, 3522-31	5.3	327
97	Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	277
96	Peptidylarginine deiminase inhibition is immunomodulatory and vasculoprotective in murine lupus. <i>Journal of Clinical Investigation</i> , 2013 , 123, 2981-93	15.9	263
95	Peptidylarginine deiminase inhibition reduces vascular damage and modulates innate immune responses in murine models of atherosclerosis. <i>Circulation Research</i> , 2014 , 114, 947-56	15.7	250
94	Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 2199-206	2.4	244
93	Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome. <i>Arthritis and Rheumatology</i> , 2015 , 67, 2990-3003	9.5	193
92	To NET or not to NET:current opinions and state of the science regarding the formation of neutrophil extracellular traps. <i>Cell Death and Differentiation</i> , 2019 , 26, 395-408	12.7	185
91	Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3354-62	2.2	152
90	EC5S ubiquitin complex is recruited by KSHV latent antigen LANA for degradation of the VHL and p53 tumor suppressors. <i>PLoS Pathogens</i> , 2006 , 2, e116	7.6	150
89	Neutrophil extracellular trap-derived enzymes oxidize high-density lipoprotein: an additional proatherogenic mechanism in systemic lupus erythematosus. <i>Arthritis and Rheumatology</i> , 2014 , 66, 25	32 ⁹ 2 ⁵ 54	4 ¹³⁴
88	Lupus neutrophils: WET以ain in understanding lupus pathogenesis. <i>Current Opinion in Rheumatology</i> , 2012 , 24, 441-50	5.3	132
87	Epstein-Barr virus latent antigen 3C can mediate the degradation of the retinoblastoma protein through an SCF cellular ubiquitin ligase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 18562-6	11.5	128
86	Proteins derived from neutrophil extracellular traps may serve as self-antigens and mediate organ damage in autoimmune diseases. <i>Frontiers in Immunology</i> , 2012 , 3, 380	8.4	122

(2016-2017)

85	In Vivo Role of Neutrophil Extracellular Traps in Antiphospholipid Antibody-Mediated Venous Thrombosis. <i>Arthritis and Rheumatology</i> , 2017 , 69, 655-667	9.5	117
84	Epstein-Barr virus nuclear antigen 3C recruits histone deacetylase activity and associates with the corepressors mSin3A and NCoR in human B-cell lines. <i>Journal of Virology</i> , 2003 , 77, 4261-72	6.6	108
83	Neutrophil extracellular traps and thrombosis in COVID-19. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 51, 446-453	5.1	99
82	Adenosine receptor agonism protects against NETosis and thrombosis in antiphospholipid syndrome. <i>Nature Communications</i> , 2019 , 10, 1916	17.4	92
81	The latency-associated nuclear antigen of Kaposils sarcoma-associated herpesvirus transactivates the telomerase reverse transcriptase promoter. <i>Journal of Biological Chemistry</i> , 2001 , 276, 22971-8	5.4	91
80	Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients. <i>Scientific Reports</i> , 2021 , 11, 1580	4.9	81
79	3005 Integrin Mac-1 Potentiates Neutrophil Adhesion and NET Release in Antiphospholipid Syndrome. <i>Journal of Clinical and Translational Science</i> , 2019 , 3, 14-14	0.4	78
78	SCFSkp2 complex targeted by Epstein-Barr virus essential nuclear antigen. <i>Molecular and Cellular Biology</i> , 2005 , 25, 1749-63	4.8	67
77	Neutrophil extracellular traps (NETs) are increased in the alveolar spaces of patients with ventilator-associated pneumonia. <i>Critical Care</i> , 2018 , 22, 358	10.8	66
76	Epstein-Barr virus nuclear antigen 3C regulates cyclin A/p27 complexes and enhances cyclin A-dependent kinase activity. <i>Journal of Virology</i> , 2004 , 78, 1981-91	6.6	65
75	Cardiovascular disease in lupus: insights and updates. Current Opinion in Rheumatology, 2013, 25, 597-60	0 5 .3	63
74	Neutrophil-mediated IFN activation in the bone marrow alters B cell development in human and murine systemic lupus erythematosus. <i>Journal of Immunology</i> , 2014 , 192, 906-18	5.3	62
73	Patients with COVID-19: in the dark-NETs of neutrophils. Cell Death and Differentiation, 2021, 28, 3125-2	31 <i>3</i> .9	61
72	Placental histology and neutrophil extracellular traps in lupus and pre-eclampsia pregnancies. <i>Lupus Science and Medicine</i> , 2016 , 3, e000134	4.6	60
71	Neutrophil calprotectin identifies severe pulmonary disease in COVID-19. <i>Journal of Leukocyte Biology</i> , 2021 , 109, 67-72	6.5	60
70	Design, synthesis, and biological evaluation of tetrazole analogs of Cl-amidine as protein arginine deiminase inhibitors. <i>Journal of Medicinal Chemistry</i> , 2015 , 58, 1337-44	8.3	55
69	Ectonucleotidase tri(di)phosphohydrolase-1 (ENTPD-1) disrupts inflammasome/interleukin 1Edriven venous thrombosis. <i>Journal of Clinical Investigation</i> , 2019 , 129, 2872-2877	15.9	52
68	Treatment of catastrophic antiphospholipid syndrome. <i>Current Opinion in Rheumatology</i> , 2016 , 28, 218-	2 7 .3	51

67	DEK-targeting DNA aptamers as therapeutics for inflammatory arthritis. <i>Nature Communications</i> , 2017 , 8, 14252	17.4	49
66	Myeloid-Specific Deletion of Peptidylarginine Deiminase 4 Mitigates Atherosclerosis. <i>Frontiers in Immunology</i> , 2018 , 9, 1680	8.4	48
65	Endothelial progenitor dysfunction associates with a type I interferon signature in primary antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 450-457	2.4	46
64	Do neutrophil extracellular traps contribute to the heightened risk of thrombosis in inflammatory diseases?. <i>World Journal of Cardiology</i> , 2015 , 7, 829-42	2.1	45
63	Activated signature of antiphospholipid syndrome neutrophils reveals potential therapeutic target. <i>JCI Insight</i> , 2017 , 2,	9.9	43
62	A cyclin-binding motif within the amino-terminal homology domain of EBNA3C binds cyclin A and modulates cyclin A-dependent kinase activity in Epstein-Barr virus-infected cells. <i>Journal of Virology</i> , 2004 , 78, 12857-67	6.6	41
61	Neutrophil extracellular traps and thrombosis in COVID-19 2020 ,		41
60	Systemic lupus erythematosus complicated by diffuse alveolar haemorrhage: risk factors, therapy and survival. <i>Lupus Science and Medicine</i> , 2015 , 2, e000117	4.6	40
59	The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 49, 464-	4 <i>6</i> 58 ³	38
58	Nm23-H1 modulates the activity of the guanine exchange factor Dbl-1. <i>International Journal of Cancer</i> , 2008 , 123, 500-10	7.5	37
57	Intercellular Interactions as Regulators of NETosis. Frontiers in Immunology, 2016, 7, 453	8.4	36
56	Neutrophil extracellular traps as a potential source of autoantigen in cocaine-associated autoimmunity. <i>Rheumatology</i> , 2017 , 56, 638-643	3.9	34
55	Regulation of matrix metalloproteinase 9 expression by Epstein-Barr virus nuclear antigen 3C and the suppressor of metastasis Nm23-H1. <i>Journal of Virology</i> , 2005 , 79, 9714-24	6.6	32
54	New (re)purpose for an old drug: purinergic modulation may extinguish the COVID-19 thromboinflammatory firestorm. <i>JCI Insight</i> , 2020 , 5,	9.9	28
53	16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. <i>Lupus</i> , 2020 , 29, 1571-1593	2.6	27
52	Increased Adhesive Potential of Antiphospholipid Syndrome Neutrophils Mediated by 2 Integrin Mac-1. <i>Arthritis and Rheumatology</i> , 2020 , 72, 114-124	9.5	27
51	Prothrombotic antiphospholipid antibodies in COVID-19 2020 ,		25
50	The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository. <i>Arthritis Care and Research</i> , 2019 , 71, 134-141	4.7	23

(2021-2021)

49	The intersection of COVID-19 and autoimmunity. Journal of Clinical Investigation, 2021,	15.9	22
48	Anti-Neutrophil Extracellular Trap Antibodies and Impaired Neutrophil Extracellular Trap Degradation in Antiphospholipid Syndrome. <i>Arthritis and Rheumatology</i> , 2020 , 72, 2130-2135	9.5	22
47	Proprotein convertase subtilisin/kexin type 9 (PCSK9) Deficiency is Protective Against Venous Thrombosis in Mice. <i>Scientific Reports</i> , 2017 , 7, 14360	4.9	18
46	Autoantibodies stabilize neutrophil extracellular traps in COVID-19. JCI Insight, 2021, 6,	9.9	18
45	The interplay between neutrophils, complement, and microthrombi in COVID-19. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021 , 35, 101661	5.3	18
44	Antimicrobial Microwebs of DNA-Histone Inspired from Neutrophil Extracellular Traps. <i>Advanced Materials</i> , 2019 , 31, e1807436	24	17
43	Genome-wide DNA methylation analysis in primary antiphospholipid syndrome neutrophils. <i>Clinical Immunology</i> , 2018 , 196, 110-116	9	17
42	Ectonucleotidase-Mediated Suppression of Lupus Autoimmunity and Vascular Dysfunction. <i>Frontiers in Immunology</i> , 2018 , 9, 1322	8.4	13
41	Characteristics of Antiphospholipid Antibody Positive Patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking. <i>Arthritis Care and Research</i> , 2020 ,	4.7	13
40	Endothelial cell-activating antibodies in COVID-19 2021 ,		13
39	Endothelial cell-activating antibodies in COVID-19 2021 , Pediatric antiphospholipid syndrome. <i>European Journal of Rheumatology</i> , 2019 , 1-10	1.7	13
·		1.7 2.6	
39	Pediatric antiphospholipid syndrome. <i>European Journal of Rheumatology</i> , 2019 , 1-10 Cluster analysis for the identification of clinical phenotypes among antiphospholipid		12
39	Pediatric antiphospholipid syndrome. <i>European Journal of Rheumatology</i> , 2019 , 1-10 Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry. <i>Lupus</i> , 2020 , 961203320940776 The bicyclomycin sensitivities of 38 bicyclomycin-resistant mutants of transcription termination protein rho and the location of their mutations support a structural model of rho based on the F(1)	2.6	12
39 38 37	Pediatric antiphospholipid syndrome. <i>European Journal of Rheumatology</i> , 2019 , 1-10 Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry. <i>Lupus</i> , 2020 , 961203320940776 The bicyclomycin sensitivities of 38 bicyclomycin-resistant mutants of transcription termination protein rho and the location of their mutations support a structural model of rho based on the F(1) ATPase. <i>Journal of Molecular Biology</i> , 2000 , 302, 565-79	2.6	12 12 11
39 38 37 36	Pediatric antiphospholipid syndrome. <i>European Journal of Rheumatology</i> , 2019 , 1-10 Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry. <i>Lupus</i> , 2020 , 961203320940776 The bicyclomycin sensitivities of 38 bicyclomycin-resistant mutants of transcription termination protein rho and the location of their mutations support a structural model of rho based on the F(1) ATPase. <i>Journal of Molecular Biology</i> , 2000 , 302, 565-79 Antiphospholipid syndrome: a clinical perspective. <i>Chinese Medical Journal</i> , 2020 , 133, 929-940 Antiphospholipid syndrome: an update for clinicians and scientists. <i>Current Opinion in</i>	2.6 6.5 2.9	12 12 11
39 38 37 36 35	Pediatric antiphospholipid syndrome. <i>European Journal of Rheumatology</i> , 2019 , 1-10 Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry. <i>Lupus</i> , 2020 , 961203320940776 The bicyclomycin sensitivities of 38 bicyclomycin-resistant mutants of transcription termination protein rho and the location of their mutations support a structural model of rho based on the F(1) ATPase. <i>Journal of Molecular Biology</i> , 2000 , 302, 565-79 Antiphospholipid syndrome: a clinical perspective. <i>Chinese Medical Journal</i> , 2020 , 133, 929-940 Antiphospholipid syndrome: an update for clinicians and scientists. <i>Current Opinion in Rheumatology</i> , 2017 , 29, 458-466 Disruption of Neutrophil Extracellular Traps (NETs) Links Mechanical Strain to Post-traumatic	2.6 6.5 2.9	12 12 11 11 10

31	Neutrophil calprotectin identifies severe pulmonary disease in COVID-19 2020,		10
30	Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients 2020 ,		10
29	NETs in APS: Current Knowledge and Future Perspectives. <i>Current Rheumatology Reports</i> , 2020 , 22, 67	4.9	10
28	Psgl-1 Deficiency is Protective against Stroke in a Murine Model of Lupus. <i>Scientific Reports</i> , 2016 , 6, 28997	4.9	10
27	Endoplasmic reticulum stress sensor IRE1[propels neutrophil hyperactivity in lupus. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	7
26	Endothelium-protective, histone-neutralizing properties of the polyanionic agent defibrotide. <i>JCI Insight</i> , 2021 , 6,	9.9	7
25	Extracellular Trap-Mimicking DNA-Histone Mesostructures Synergistically Activate Dendritic Cells. <i>Advanced Healthcare Materials</i> , 2019 , 8, e1900926	10.1	6
24	Cryptic conspirators: a conversation about thrombocytopenia and antiphospholipid syndrome. <i>Current Opinion in Rheumatology</i> , 2019 , 31, 231-240	5.3	6
23	Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome <i>Seminars in Immunopathology</i> , 2022 , 1	12	5
22	Autoantibodies stabilize neutrophil extracellular traps in COVID-19 2021 ,		5
21	Antineutrophil properties of natural gingerols in models of lupus. JCI Insight, 2021, 6,	9.9	5
20	A 37-Year-Old Man With Primary Antiphospholipid Syndrome Presenting With Respiratory Distress and Worsening Toe Ischemia. <i>Arthritis Care and Research</i> , 2017 , 69, 1253-1259	4.7	4
19	Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository. <i>Journal of Thrombosis and Haemostasis</i> , 2019 , 17, 2069-2080	15.4	4
18	The role of neutrophil extracellular traps and TLR signaling in skeletal muscle ischemia reperfusion injury. <i>FASEB Journal</i> , 2020 , 34, 15753-15770	0.9	4
17	Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository. <i>Journal of Rheumatology</i> , 2021 , 48, 541-547	4.1	4
16	Tenosynovitis Revealed by Fungal Culture in a Patient Treated with Infliximab. <i>Journal of Rheumatology</i> , 2018 , 45, 284-285	4.1	3
15	Digital ischaemia secondary to adalimumab-induced antiphospholipid syndrome. <i>BMJ Case Reports</i> , 2020 , 13,	0.9	3
	COVID-19 and antiphospholipid antibodies: A position statement and management guidance from		

LIST OF PUBLICATIONS

13	Reply. Arthritis and Rheumatology, 2016 , 68, 1321-2	9.5	2
12	Treatment of thrombotic antiphospholipid syndrome in adults and children. <i>Current Opinion in Rheumatology</i> , 2020 , 32, 215-227	5.3	2
11	Endothelium-protective, histone-neutralizing properties of the polyanionic agent defibrotide 2021,		2
10	Response to: Wonocyte type I interferon signature in antiphospholipid syndrome is related to pro-inflammatory monocyte subsets, hydroxychloroquine and statin uselby van den Hoogen et al. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, e82	2.4	1
9	Defibrotide inhibits antiphospholipid antibody-mediated NET formation and venous thrombosis. <i>Arthritis and Rheumatology</i> , 2021 ,	9.5	1
8	Understanding the Pathophysiology of Thrombotic APS through Animal Models. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
7	The IRE1Istress Signaling Axis Is a Key Regulator of Neutrophil Antimicrobial Effector Function. <i>Journal of Immunology</i> , 2021 ,	5.3	1
6	Utilizing type I interferon expression in the identification of antiphospholipid syndrome subsets. <i>Expert Review of Clinical Immunology</i> , 2021 , 17, 395-406	5.1	1
5	Circulating Calprotectin as a Predictive and Severity Biomarker in Patients with COVID-19. <i>Diagnostics</i> , 2022 , 12, 1324	3.8	1
4	Pediatric antiphospholipid syndrome: clinical features and therapeutic interventions in a single center retrospective case series <i>Pediatric Rheumatology</i> , 2022 , 20, 17	3.5	Ο
3	Eighty-Five Cases of Lymphoma in a Solid Organ Transplant (SOT) Population: Risk, Treatment, and Histologic Subtype <i>Blood</i> , 2007 , 110, 1367-1367	2.2	
2	Clinical and laboratory characteristics of Brazilian versus non-Brazilian primary antiphospholipid syndrome patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) clinical database and repository. <i>Advances in Rheumatology</i> , 2021 , 61, 64	3	

Tissue injurythe biology **2021**, 271-285